CT-ATLAS-HOLDINGS
30.9.2020 11:17:07 CEST | Business Wire | Press release
Atlas Holdings announced today that it has completed its acquisition of Permasteelisa Group, a global leader in the engineering, project management, manufacturing, installation and after-sales service of advanced building facades, architectural envelopes and interiors. Permasteelisa Group has partnered with architects on more than 3,500 projects that have transformed skylines around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005357/en/
Permasteelisa Group’s three brands, Permasteelisa, Gartner and Scheldebouw, are recognized as the premier integrated providers of high quality, bespoke curtain wall solutions in the world. Collectively, the company employs more than 4,500 associates, designing, fabricating and installing premier projects out of locations in 30 countries, including nine production facilities and eight principal design offices.
“Permasteelisa Group is trusted by the world’s most visionary architects to turn their designs into reality and has a 100 percent project delivery record over its five decades of market leadership. Combining this unique positioning in the market with Atlas’ construction and manufacturing industry expertise is a ‘win-win’ for the company, its associates and its customers,” said Timothy Fazio, Atlas Holdings Co-Founder and Managing Partner. “We are thrilled to welcome Permasteelisa Group to the Atlas Family.”
“Permasteelisa Group has brought to life some of the world’s most iconic buildings,” said Peter Bacon, Operating Partner of Atlas Holdings. “The company’s ability to execute large, complex projects is simply unmatched in the curtain wall industry.”
Permasteelisa Group’s notable projects include the Shard in London, Apple’s HQ campus in Cupertino, the World Trade Center redevelopment in New York, where the group worked on 1WTC, 3WTC and 7WTC, the World Financial Center in Shanghai, New York City’s One Vanderbilt and the International Commerce Center in Hong Kong.
“We could not have found a better partner to strengthen our company today and build a brighter future than Atlas Holdings,” said Klaus Lother, Permasteelisa Group Chief Executive Officer. “Our clients trust us to get the job done quickly and flexibly, wherever a project demands, and Atlas’ global footprint and directly relevant experience in the construction and manufacturing arenas is a perfect fit. Most importantly, they have a long-term focus and share our core values; a commitment to environmental stewardship, employee safety and delivering superior customer service. Our team is thrilled to begin working with Atlas.”
###
About Atlas Holdings
Headquartered in Greenwich, Connecticut and founded in 2002, Atlas and its affiliates own and operate 22 platform companies which employ more than 25,000 associates at more than 200 facilities worldwide. Atlas operates in sectors such as aluminum processing, automotive, building materials, capital equipment, construction services, food manufacturing and distribution, packaging, paper, power generation, pulp, supply chain management and wood products. Atlas’ companies together generate more than $6 billion in revenues annually. For additional information, please visit www.atlasholdingsllc.com .
About Permasteelisa Group
The Permasteelisa Group operates worldwide in the design, production and installation of architectural enclosures, curtain walls and interior systems, placing itself in a position of absolute leadership in the global reference market. In all of its projects the Group contributes with its Know-How and its experience, especially for the "Special Features Buildings," from the design phase to the successful completion, reaching the architectural expectations of its customers. Among the Group's achievements, there are some of the most prestigious contemporary architectural works in the world such as the Sydney Opera House (the first building to use the curtain wall system extensively), Eight Spruce in lower Manhattan (also known as Beekman Tower), The Shard and 20 Fenchurch Street in London, the revolutionary Guggenheim Museum in Bilbao, the extraordinary Walt Disney Concert Hall in Los Angeles and the MoMA in New York. To discover more, please visit www.permasteelisagroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005357/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
